[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"imaging-techniques\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:imaging-techniques":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100622634","micro-ultrasound-for-detecting-clinically-significant-prostate-cancer-in-active-surveillance-100622634",false,"NCT07386171","Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance","Evaluating Micro-Ultrasound as a Supplemental Imaging Modality for Clinically Significant Prostate Cancer Detection in Men With Negative or Stable Multiparametric MRI on Active Surveillance or at Diagnosis","MUS-AS","Inclusion Criteria:\n\n* Male participants aged 45 to 75 years\n* Localized prostate cancer on active surveillance or newly diagnosed and eligible for active surveillance\n* Negative multiparametric MRI (PI-RADS ≤2) or stable mpMRI findings on surveillance\n* Prior prostate biopsy showing Grade Group 1, or Grade Group 2 (Gleason 3+4) with ≤10% pattern 4\n* PSA ≤15 ng\u002FmL\n* PSA density \\\u003C0.15 ng\u002FmL\u002Fcc\n* Clinical stage ≤T2a\n* Life expectancy \\>10 years\n* Ability to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Prior definitive treatment for prostate cancer (e.g., radical prostatectomy, radiotherapy)\n* Prior prostate surgery that may affect biopsy or imaging interpretation\n* Contraindication to prostate biopsy\n* Active urinary tract infection or prostatitis\n* Inability to tolerate the biopsy procedure or follow study procedures","MALE","45 Years","75 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease. Multiparametric MRI (mpMRI) is widely used to guide diagnosis and follow-up, but it can miss clinically significant prostate cancer and may be limited by access, cost, and variability in interpretation.\n\nMicro-ultrasound is a high-resolution ultrasound technique that may improve real-time detection of suspicious prostate lesions using a standardized scoring system (PRI-MUS). The purpose of this study is to evaluate the diagnostic performance of micro-ultrasound for detecting clinically significant prostate cancer in men with negative or stable mpMRI findings, either at initial diagnosis or during active surveillance follow-up.\n\nParticipants will undergo micro-ultrasound assessment of the prostate. Areas considered suspicious on micro-ultrasound may be targeted for biopsy, followed by systematic prostate sampling. Biopsy results will be used as the reference standard to determine whether clinically significant prostate cancer is present.\n\nThe study will assess measures such as sensitivity, specificity, and predictive values of micro-ultrasound, as well as procedure-related complications.",[28,29,30],"Prostate Cancer","Active Surveillance for Prostate Cancer","Imaging Techniques",[32,33,34,35,36,37],"Active Surveillance Prostate Cancer","Prostate Cancer Imaging","Micro-ultrasound","Multiparametric MRI","Clinically significant prostate cancer","Targeted-Systematic biopsy","NOT_YET_RECRUITING","2026-01-27",{"date":41,"type":42},"2026-02-04","ACTUAL",{"date":44,"type":22},"2026-03-01",{"date":46,"type":22},"2027-06-01",{"name":48,"class":49},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":50},"100587200","phase-2-using-xe-mri-to-guide-radiation-therapy-for-lung-cancer-100587200","NCT06925295","Using Xe MRI to Guide Radiation Therapy for Lung Cancer","Image-Based Functionally Adapted Radiation Therapy for Lung Cancer","(XeRTLC)","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial\n\n1. Aged 18-80 years\n2. Willing and able to provide informed consent and adhere to visit\u002Fprotocol schedules (Consent must be given before any study procedures are performed.)\n3. Clinical diagnosis of lung cancer made by a board-certified oncologist with intent to treat with stereotactic body radiation therapy. We will not exclude individuals based on cancer type or severity of disease with the exception of the below criteria\n\nExclusion Criteria:\n\nSubjects presenting with any of the following will not be included in the trial:\n\n1. Subject is less than 18 years old or incarcerated\n2. MRI is contraindicated based on responses to MRI screening questionnaire\n3. Subject is pregnant or lactating\n4. Resting oxygen saturation \\\u003C90% on supplemental oxygen\n5. Respiratory illness of bacterial or viral etiology within 30 days of planned treatment\n6. Subject has history of any known ventricular cardiac arrhythmia\n7. Subject has history of cardiac arrest within the last year\n8. Subject has prior history of cancer treatment with radiation therapy to the lung\n9. Subject has concurrent cancer treatment with agents associated with increased risk of radiation pneumonitis (e.g. immunotherapy, chemotherapy)\n10. Subject does not fit into 129Xe vest coil used for MRI\n11. Subject cannot hold his\u002Fher breath for 15 seconds\n12. Subject deemed unlikely to be able to comply with instructions during imaging\n13. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements","ALL","18 Years","80 Years",{"count":63,"type":22},15,[65],"PHASE2","The purpose of this research study is to explore using MRI scans with xenon to better image lung function, how lung function changes after radiation therapy, and to guide radiation therapy away from parts of the lung that have good function. This project is foundational to performing additional studies to establish if novel MRI imaging can serve as a guidance tool for lung cancer radiation treatment.",[30],[69,70,71],"Lung cancer","Xenon","Imaging","RECRUITING","2025-12-30",{"date":75,"type":42},"2026-01-02",{"date":77,"type":42},"2025-08-30",{"date":79,"type":22},"2027-01",{"name":81,"class":49},"Sean Fain"]